Published in Arch Intern Med on July 12, 1999
Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ (2004) 1.18
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health (2007) 0.79
Validation of a decision model for preventive pharmacological strategies in postmenopausal women. Eur J Epidemiol (2005) 0.76
The threshold approach to clinical decision making. N Engl J Med (1980) 8.51
Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) (1981) 8.48
On the elicitation of preferences for alternative therapies. N Engl J Med (1982) 7.85
Cigarette smoking in pregnancy: its influence on birth weight and perinatal mortality. Br Med J (1972) 7.69
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ (2009) 7.64
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med (1991) 7.62
Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med (1993) 6.72
Screening for HIV: can we afford the false positive rate? N Engl J Med (1987) 5.94
Screening for prostate cancer. A decision analytic view. JAMA (1994) 5.83
Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med (2001) 5.05
Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med (1981) 4.34
Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med (1990) 4.32
Fallacy of the five-year survival in lung cancer. N Engl J Med (1978) 4.23
Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study. JAMA (1986) 4.20
Therapeutic decision making: a cost-benefit analysis. N Engl J Med (1975) 3.89
Biochemical properties of hormone-sensitive adenylate cyclase. Annu Rev Biochem (1980) 3.79
An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Am J Cardiol (1992) 3.66
Towards the simulation of clinical cognition. Taking a present illness by computer. Am J Med (1976) 3.62
The Markov process in medical prognosis. Med Decis Making (1983) 3.58
Decision analysis. N Engl J Med (1987) 3.41
Contentious screening decisions: does the choice matter? N Engl J Med (1997) 3.28
Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA (1997) 3.18
Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol (1998) 3.16
Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med (1993) 3.03
Relationship between the beta-adrenergic receptor and adenylate cyclase. J Biol Chem (1977) 2.99
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA (1999) 2.97
Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity. J Biol Chem (1990) 2.96
When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol (2001) 2.84
Decision analysis: a progress report. Ann Intern Med (1987) 2.82
Purification of the regulatory component of adenylate cyclase. Proc Natl Acad Sci U S A (1980) 2.81
Effect of failed extubation on the outcome of mechanical ventilation. Chest (1997) 2.77
The toss-up. N Engl J Med (1981) 2.71
Variations in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. JAMA (1991) 2.71
Type C particle-positive and type C particle-negative rat cell lines: characterization of the coding capacity of endogenous sarcoma virus-specific RNA. J Virol (1976) 2.67
Reconstitution of hormone-sensitive adenylate cyclase activity with resolved components of the enzyme. J Biol Chem (1978) 2.64
A residents' training program for the development of smoking intervention skills. Arch Intern Med (1988) 2.61
A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med (1982) 2.56
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol (1999) 2.50
A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med (1982) 2.49
Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem (1988) 2.45
Epilepsy in childhood: findings from the National Child Development Study. Br Med J (1980) 2.37
Deciding about screening. Ann Intern Med (1993) 2.36
Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med (1995) 2.32
Asymptomatic bacteriuria in girl entrants to Dundee primary schools. Br Med J (1969) 2.32
Prenatal diagnosis: a directive approach to genetic counseling using decision analysis. Yale J Biol Med (1977) 2.28
Resolution of some components of adenylate cyclase necessary for catalytic activity. J Biol Chem (1977) 2.20
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J (2003) 2.20
Treatment of early Lyme disease. Am J Med (1992) 2.18
Phospholipase C-beta 1 is a GTPase-activating protein for Gq/11, its physiologic regulator. Cell (1992) 2.17
Occult intracranial aneurysms in polycystic kidney disease. When is cerebral arteriography indicated? N Engl J Med (1983) 2.12
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
Characterizatiion of rat genetic sequences of Kirsten sarcoma virus: distinct class of endogenous rat type C viral sequences. J Virol (1976) 2.09
Reconstitution of agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11, and phospholipase C-beta 1. J Biol Chem (1992) 2.06
Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med (1985) 2.05
The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J (2001) 2.01
Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med (1998) 2.01
Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA (1995) 1.95
The epidemiology of delays in a teaching hospital. The development and use of a tool that detects unnecessary hospital days. Med Care (1989) 1.91
Reconstitution of catecholamine-stimulated guanosinetriphosphatase activity. Biochemistry (1983) 1.87
Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol (1999) 1.87
You're never too old. N Engl J Med (1993) 1.86
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
Decision analysis and the implementation of research findings. BMJ (1998) 1.85
The amniocentesis decision: ten years of decision analytic experience. Birth Defects Orig Artic Ser (1987) 1.85
Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr (1991) 1.81
Regulation of phospholipase C-beta1 by Gq and m1 muscarinic cholinergic receptor. Steady-state balance of receptor-mediated activation and GTPase-activating protein-promoted deactivation. J Biol Chem (1996) 1.80
Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol Rev (1982) 1.79
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol (2001) 1.74
A prospective randomized trial of outpatient versus inpatient cardiac catheterization. N Engl J Med (1988) 1.73
Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int (2006) 1.73
Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Rapid Early Action for Coronary Treatment (REACT) Study Group. Am Heart J (1999) 1.73
Rapid early action for coronary treatment: rationale, design, and baseline characteristics. REACT Research Group. Acad Emerg Med (1998) 1.69
Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. J Biol Chem (1991) 1.63
Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. J Neurosci (1998) 1.62
The effect of activating ligands on the intrinsic fluorescence of guanine nucleotide-binding regulatory proteins. J Biol Chem (1987) 1.61
The editor's correspondence: analysis of patterns appearing in selected specialty and general journals. Am J Cardiol (1983) 1.61
Early discharge after mastectomy. A safe way of diminishing hospital costs. Am Surg (1987) 1.61
Rapid GTP binding and hydrolysis by G(q) promoted by receptor and GTPase-activating proteins. Proc Natl Acad Sci U S A (1999) 1.61
Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making (2005) 1.60
A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol (1994) 1.59
Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology (1995) 1.59
Routine preoperative screening for HIV. Does the risk to the surgeon outweigh the risk to the patient? JAMA (1988) 1.59
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart (2003) 1.55
Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol (2001) 1.55
Catecholamine-stimulated GTPase cycle. Multiple sites of regulation by beta-adrenergic receptor and Mg2+ studied in reconstituted receptor-Gs vesicles. J Biol Chem (1986) 1.54
Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med (1994) 1.54
A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol (2001) 1.53